Investigating a new immunotherapy approach for ovarian cancer
Mechanisms of Th17-DC immunotherapy for ovarian cancer
This study is testing a new treatment for advanced ovarian cancer that combines a special immune therapy with a vaccine to help your body fight the cancer better, and it’s looking for patients to see how well it works and if it’s safe.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project ID | NIH-11051773 on NIH RePORTER |
What this research studies
This research explores a novel immunotherapy approach for ovarian cancer that combines anti-PD-1 treatment with Th17-inducing dendritic cell vaccination. The goal is to enhance the immune response against tumors by stimulating anti-tumor T cell immunity and reducing immune suppression in the tumor microenvironment. The study will evaluate the role of B cells in the effectiveness of this combined treatment, aiming to improve patient outcomes in advanced stages of ovarian cancer. Patients may be involved in trials that assess the safety and efficacy of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with stage III or IV ovarian cancer who have not responded well to existing therapies.
Not a fit: Patients with early-stage ovarian cancer or those who have not been diagnosed with ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced ovarian cancer.
How similar studies have performed: Previous studies have shown promising results with Th17-DC vaccination in improving responses to anti-PD-1 therapy, indicating potential for success in this approach.
Where this research is happening
Little Rock, United States
- Univ of Arkansas for Med Scis — Little Rock, United States (Active)
Researchers
- Principal investigator: Cannon, Martin J — Univ of Arkansas for Med Scis
- Study coordinator: Cannon, Martin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.